<unk>  (or cyclic pyranopterin monophosphate, cPMP), sold under the brand name Nulibry, is a medication used to reduce the risk of death due to a rare genetic disease known as molybdenum cofactor deficiency type A. The most common side effects include complications related to the intravenous line, fever, respiratory infections, vomiting, gastroenteritis, and diarrhea.<unk>  was approved for medical use in the United States in February 2021. It is the first medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of molybdenum cofactor deficiency type A.
Fosdenopterin
Tetrahydrobiopterin
Toxidrome
Hematoporphyrin
Lipochrome
Epoetin beta
Hemichrome
Neopterin